Polymerase Chain Reaction, Nuclease Digestion, and Mass Spectrometry Based Assay for the Trinucleotide Repeat Status of the Fragile X Mental Retardation 1 Gene

Department of Chemistry, University of California Davis, One Shields Avenue, Davis, California 95616, USA.
Analytical Chemistry (Impact Factor: 5.64). 07/2009; 81(13):5533-5540. DOI: 10.1021/ac9008918
Source: PubMed


CGG repeat expansions in the 5' noncoding region of the fragile X mental retardation 1 gene (FMR1) give rise to both neurodevelopmental and neurodegenerative human diseases depending on the length of the expansion. Expansions beyond 200 repeats (full mutation) generally result in gene silencing and fragile X syndrome (FXS), the leading heritable form of cognitive impairment and autism. Smaller expansions (55-200 CGG repeats; "premutation") give rise to the neurodegenerative disorder fragile X-associated tremor/ataxia syndrome (FXTAS) through an entirely distinct, toxic mRNA gain-of-function mechanism. A rapid means for both high-risk and newborn screening for allele size would provide a greater opportunity for early intervention and family counseling as well as furnish critical data on repeat size distribution and expanded allele frequencies. In the current work, we propose a novel mass spectrometry (MS) based method for the rapid identification of expanded CGG repeats to complement a recently described polymerase chain reaction (PCR) method for large population screening. In this combined approach, the optimized PCR method is used to amplify the relevant region of FMR1, followed by extensive nonspecific nuclease digestion. The resulting oligonucleotides are analyzed by MS in a manner that provides the relative proportion of triplet repeat oligonucleotides in seconds per sample. This assay enables swift and reproducible detection of expanded CGG alleles using a single blood spot and in principle is suitable for large scale studies and newborn screening. Moreover, this analytical scheme establishes a unique new intersection of MS with molecular biology, with potential for significant interdisciplinary impact.

Download full-text


Available from: Eric D. Dodds, May 16, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Summary Chapter 1 addresses general aspects of neurodevelopmental disorders and gives an outline of this thesis. Neurodevelopmental disorders (NDD), are an important health care problem with a prevalence of 2-3% in the general population. The widespread etiological causes for NDD comprise exogenic factors (teratogens, infections and trauma) and genetic causes (including metabolic diseases). The complicated diagnostic work-up in NDD is described. Chapter 2 describes the importance of metabolic investigations in the diagnostic pathway of NDD. We studied the yield of metabolic investigations in patients with neurodevelopmental disorders of unknown origin and found a yield of 2.8 % despite performed metabolic investigations before referral. As seen in this study, additional metabolic investigations can even extend the metabolic yield in an already screened population. Chapter 3 describes the findings of MRI scans in patients with unexplained NDD. In 30.7 % of the patients abnormal MRI scans were observed and in 5.4 % the MRI scans lead to an etiologic diagnosis. This study shows in a large population of patients with NDD that neurological findings are indicative for having an abnormal or diagnostic MRI. In our specialised centre 5.4 % of the patients had a diagnostic MRI scan, despite initial metabolic and genetic investigations before referral. This study confirms for the first time in a large population of patients with unexplained NDD, the value of an MRI scan of the brain, in the diagnostic work-up for NDD. Chapter 4 describes the yield of MRI imaging in patients with NDD in association with dysmorphic features. Dysmorphic features could indicate an altered embryonic, foetal or post-natal development, likely to increase the chance of abnormal developmental patterning of the brain. This study showed a higher number of craniofacial dysmorphic features in patients with NDD increasing the yield of brain abnormalities of those patients. This might aid the search for an etiological diagnosis. In chapter 5 the frequency of specific pregnancy and delivery features in children with NDD was compared with the frequency of pregnancy and delivery features in children of the general Dutch population. The study established associations between NDD and gestational diabetes, polyhydramnion, postterm pregnancy, Low Birth Weight (LBW<2500gram) and face position. In chapter 6 a patient with developmental delay and several facial characteristics reminiscent of Wolf-Hirschhorn syndrome is described. This patient carries a terminal 4p16.3 deletion of minimally 1.691 and maximally 1.698 Mb, containing the FGFRL1 gene, but not including the WHSC1 gene. Given its expression pattern and its involvement in bone and cartilage formation during embryonic development the FGFRL1 gene represents a plausible candidate gene for part of the facial characteristics of Wolf-Hirshhorn syndrome in 4p16.3 deletion patients. The final chapter, describes a future prospective for metabolic diseases, radiology and clinical genetics in the diagnostic work-up for NDD. Theoretically, a diagnostic multidisciplinary approach should have a higher yield in finding an etiological diagnosis for NDD compared to a soloist specialist approach, because the integration of different specialist’s knowledge will provide more effective interpretation of patient investigations.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study demonstrates that methyl-CpG-binding PCR (MB-PCR) is a rapid and simple method for detecting fragile X syndrome (FXS) in males, which is performed by verifying the methylation status of the FMR1 promoter in bloodspots. Proteins containing methyl-CpG-binding (MB) domains can be freeze-stored and used as stocks, and the entire test requires only a few hours. The minimum amount of DNA required for the test is 0.5 ng. At this amount, detection sensitivity is not hampered, even mixing with excess unmethylated alleles up to 320 folds. We examined bloodspots from 100 males, including 24 with FXS, in a blinded manner. The results revealed that the ability of MB-PCR to detect FMR1 promoter methylation was the same as that of Southern blot hybridization. Since individuals with 2 or more X chromosomes generally have methylated FMR1 alleles, MB-PCR cannot be used to detect FXS in females.
    BioMed Research International 11/2009; 2009:643692. DOI:10.1155/2009/643692 · 2.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Healthy women who carry a ''premutation'' in the FMR1 gene (or fragile X mental retardation protein) can pass on a further mutated copy of FMR1 to either male or female offspring, leading to fragile X syndrome (FXS). Premutation carriers do not have manifestations of FXS in cognitive deficits, behavioral abnormalities, or classic physical features, but are at increased risk for development of the ''fragile X-associated disorders'': premature ovarian insufficiency and fragile X-associated tremor and ataxia syndrome. When considering widespread prenatal carrier screening programs for fragile X, significant resources must be available for at-risk individuals, including counseling, accurate diagnostic options for fetal testing, and choice regarding continuation of a pregnancy. Further attention is needed to develop and utilize inexpensive screening tests with adequate sensitivity and specificity to reduce barriers to screening for the population. Recently newer methodologies for high-throughput and inexpensive screening assays, which correctly detect expanded alleles in premutation and full mutation patients with a high degree of sensitivity, show significant promise for reduction in cost with rapid turn around times. With the introduction of widespread screening, individuals will be made aware not only of their risk for offspring with FXS, but will also have knowledge of the potential risk to develop the adult-onset conditions- FXPOI and FXTAS. This introduces more complex counseling challenges. All individuals identified as carriers of intermediate or premutation alleles should be referred for genetic counseling to properly convey risks for allele expansion and to discuss possible future risks of fragile X-associated disease.
    Obstetrics and Gynecology Clinics of North America 03/2010; 37(1):61-70, Table of Contents. DOI:10.1016/j.ogc.2010.03.004 · 1.38 Impact Factor
Show more